A highly anticipated clinical trial found no advantage to an invasive strategy for patients with stable coronary artery disease.

A late-breaking trial’s surprising results remind providers not to extrapolate results from one condition to another.

For Afib patients, lowering the risk of stroke is crucial. A late-breaking trial presented at AHA Scientific Sessions compares anti-thrombotic agents when coronary disease is also a factor.